<?xml version="1.0" encoding="UTF-8"?>
<p>A patient was considered to have laboratory-confirmed SARS if there was a positive RT-PCR result from two or more clinical specimens, either from different sites or tested in different laboratories, obtained from patients before or after death, or if there was seroconversion by enzyme-linked immunosorbent assay, indirect fluorescent antibody test or neutralization assay.
 <xref rid="dyaa033-B17" ref-type="bibr">
  <sup>17</sup>
 </xref> Similar to MERS, serologic testing for IgG antibodies was developed for SARS coronavirus. Treatment of SARS involved combination therapy of lopinavir and ritonavir and was associated with substantial clinical benefit with fewer adverse clinical outcomes.
 <xref rid="dyaa033-B18" ref-type="bibr">
  <sup>18</sup>
 </xref> A broad-spectrum antiviral nucleotide prodrug named remdesivir presented potent efficacy for the treatment of MERS coronavirus and SARS coronavirus in preclinical studies.
 <xref rid="dyaa033-B15" ref-type="bibr">
  <sup>15</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dyaa033-B16" ref-type="bibr">
  <sup>16</sup>
 </xref>
</p>
